All regulations
Nonrulemaking
FDA
FDA-2021-P-0567
Requests that the FDA declare that the drug product, Solifenacin Oral Solution, 1 mg/mL is suitable for submission in an Abbreviated New Drug Application
Documents
6
Comments
0
Description
CLOSED
Key Dates
Comment Period OpensJul 7, 2021
Documents
| Type | Title | Status |
|---|---|---|
Other |
Keywords
CLOSED
an ANDA
suitable for submission in
1 mg/mL is
Solifenacin Oral Solution
declare that the drug product
Liqmeds Limited, UK
M A Pharmaceutical Consulting Inc
CDER
Data from Regulations.gov